Spaltudaq Corp. Announces Identification of Broadly and Potently Neutralizing Human HIV Antibodies and Change of Company Name to Theraclone Sciences, Inc.

SEATTLE--(Business Wire)--
Theraclone Sciences, a biopharmaceutical company formerly known as Spaltudaq,
focused on the discovery and development of human antibodies, announced results
from its HIV antibody discovery program at the HIV Immunobiology Meeting of the
Keystone Symposia Global Health Series earlier this week.

Theraclone has been working to identify and generate neutralizing monoclonal
antibodies from rare HIV-infected patients who appear to have slow progression
of their disease. Such patients are relatively rare, and, despite being
infected, are clinically asymptomatic. Sera from such patient samples often have
the ability to neutralize a broad range of HIV viruses, suggesting the
possibility of antibodies capable of controlling HIV infection and progression.

On Monday, Theraclone announced the identification of two new antibodies that
have potent neutralizing activity over a broad range of HIV viruses. After more
than 15 years of research and prior to these results, only a handful of
human-derived antibodies had been reported that broadly neutralize HIV in vitro.
Such antibodies may be useful therapeutically and may also provide the basis to
"reverse engineer" a vaccine that is capable of inducing such protective
antibodies in patients.

"We are very excited about these findings," said David Fanning, President and
CEO of Theraclone. "We undertook this work to demonstrate proof-of-concept that
such antibodies exist in these patients and that they are obtainable using our
approach. We look forward to further testing and characterization of these
antibodies as potential therapeutic candidates and to the potential
identification of additional broadly and potently neutralizing antibodies in
2009 and 2010."

Theraclone Sciences, Inc., announced that its name will be changed from
Spaltudaq, effective March 30th.

"We wanted to select a name that highlights our ability to clone and express
clinically relevant, naturally fully human antibodies for clinical and
commercial benefit," said David Fanning.

Theraclone`s core technology is called I-STAR, which stands for In-Situ
Therapeutic Antibody Rescue. The technology enables the discovery and synthesis
of human therapeutic monoclonal antibodies directly from human memory B cells.
As a class, therapeutic monoclonal antibodies represent the fastest-growing drug
category. The company is focused on infectious disease and inflammation and has
programs in influenza, HIV, and human cytomegalovirus.

About Theraclone Sciences, Inc.

Theraclone Sciences, Inc., is a biopharmaceutical company committed to the
development and commercialization of therapeutic monoclonal antibodies for the
treatment of infectious disease and inflammation. Theraclone is a privately held
organization with venture investment from ARCH Venture Partners, Canaan Partners
and Healthcare Ventures, and is headquartered in Seattle. For additional
information, please visit www.theraclone-sciences.com.

Theraclone Sciences, Inc.
David Fanning, 206-805-1603
dfanning@theraclone-sciences.com

Copyright Business Wire 2009